Heron Therapeutics, Inc.
HRTX Healthcare Biotechnology
Heron Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $154.9 million, up 7.36% from fiscal 2024. In the quarter to June 2026, revenue grew 1.25%, EPS fell 93.6%, free cash flow grew 78.8% and total debt fell 18.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow HRTX
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
51.14 | 172.38 | 332.37 | 390.97 | 208.49 | 157.58 | 84.85 | 80.41 | 59.28 | 46.63 |
Receivables |
1.96 | 41.87 | 64.65 | 39.88 | 41.85 | 35.50 | 52.05 | 60.14 | 78.88 | 89.59 |
Inventory |
5.34 | 10.11 | 39.03 | 24.97 | 41.91 | 48.38 | 54.57 | 42.11 | 53.16 | 92.75 |
Total current assets |
62.14 | 228.06 | 447.25 | 479.06 | 314.20 | 254.42 | 205.44 | 188.77 | 209.01 | 238.07 |
Property, Plant, Equpment (Net) |
5.08 | 5.98 | 14.68 | 19.62 | 22.74 | 23.73 | 22.16 | 20.17 | 14.86 | 12.40 |
Long-term assets (Other) |
0.26 | 0.26 | 0.25 | 0.35 | 0.35 | 17.72 | 15.71 | 8.13 | 6.48 | 5.41 |
Total non-current assets |
5.34 | 6.24 | 14.93 | 33.72 | 39.36 | 51.28 | 45.52 | 33.73 | 24.13 | 17.81 |
Total Assets |
67.48 | 234.31 | 462.18 | 512.78 | 353.56 | 305.71 | 250.95 | 222.51 | 233.15 | 255.88 |
Notes Payable |
2.91 | 28.68 | 4.57 | 5.62 | 7.05 | — | — | — | — | — |
Accounts Payable |
6.81 | 18.77 | 16.86 | 2.76 | 0.53 | 3.80 | 3.23 | 3.24 | 11.71 | 8.99 |
Accrued Expenses |
21.62 | 35.78 | 37.87 | 49.86 | 63.56 | 38.98 | 37.88 | 31.52 | 34.96 | 35.87 |
Current Revenue (Deferred) |
1.10 | 2.76 | — | — | — | — | — | — | — | — |
Total current liabilities |
38.73 | 103.17 | 92.02 | 96.71 | 102.50 | 71.06 | 82.36 | 79.69 | 91.46 | 96.10 |
Long Term Debt (Total) |
50.00 | — | — | 12.24 | 14.56 | 149.08 | 149.28 | 173.75 | 174.73 | 140.64 |
Non-current Liabilities (Other) |
0.00 | — | — | — | 0.00 | — | 0.24 | 0.24 | 0.62 | 4.81 |
Total non-current liabilities |
50.00 | — | — | 12.24 | 14.56 | 157.08 | 155.02 | 176.79 | 175.34 | 145.45 |
Total liabilities |
88.73 | 103.17 | 92.02 | 108.95 | 117.06 | 228.14 | 237.38 | 256.48 | 266.80 | 241.54 |
Additional Paid In Capital |
564.34 | 913.96 | 1,330.19 | 1,568.32 | 1,628.07 | 1,689.99 | 1,807.86 | 1,870.53 | 1,884.41 | 1,951.19 |
Preferred Stock (Total) |
— | — | — | — | — | — | — | — | — | 1.05 |
Common Stock (Net) |
0.39 | 0.65 | 0.78 | 0.90 | 0.91 | 1.02 | 1.19 | 1.50 | 1.52 | 1.88 |
Retained Earnings |
(585.97) | (783.45) | (960.72) | (1,165.47) | (1,392.75) | (1,613.43) | (1,795.45) | (1,906.01) | (1,919.59) | (1,939.79) |
Common Equity (Total) |
(21.25) | 131.14 | 370.16 | 403.84 | 236.49 | 77.57 | 13.57 | (33.97) | (33.65) | 13.28 |
Shareholders Equity (Total) |
(21.25) | 131.14 | 370.16 | 403.84 | 236.49 | 77.57 | 13.57 | (33.97) | (33.65) | 14.33 |
Shareholders Equity and Liabilities (Total) |
67.48 | 234.31 | 462.18 | 512.78 | 353.56 | 305.71 | 250.95 | 222.51 | 233.15 | 255.88 |
Shares (Common) |
39.55 | 64.61 | 78.17 | 90.30 | 91.31 | 102.01 | 119.16 | 150.29 | 152.13 | 188.31 |
Shares (Preferred) |
— | — | — | — | — | — | — | — | — | 0.07 |
Shareholders Equity (Tangible) |
(21.25) | 131.14 | 370.16 | 403.84 | 236.49 | 77.57 | 13.57 | (33.97) | (33.65) | 14.33 |
Net Debt |
(1.14) | (172.38) | (332.37) | (378.73) | (193.93) | (8.50) | 64.43 | 93.34 | 115.44 | 94.01 |
Total Debt |
50.00 | 28.68 | 4.57 | 12.24 | 14.56 | 149.08 | 149.28 | 173.75 | 174.73 | 140.64 |